Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
METiS Announces Pan-RAF Inhibitor License Agreement with Voronoi
Details : Under the terms of this license agreement, METiS will receive exclusive license to develop and commercialize Voronoi’s pan-RAF inhibitor program worldwide.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : $1.7 million
September 13, 2022
Lead Product(s) : ORIC-114
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : ORIC Pharmaceuticals
Deal Size : $621.0 million
Deal Type : Licensing Agreement
Oric Pharma Teams up With Korean firm to Expand Precision Oncology Pipeline
Details : ORIC secured exclusive rights worldwide excluding the People’s Republic of China, Hong Kong, Macau and Taiwan (the ORIC Territory) for the development and commercialization of ORIC-114.
Product Name : ORIC-114
Product Type : Other Small Molecule
Upfront Cash : $5.0 million
October 19, 2020
Lead Product(s) : ORIC-114
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : ORIC Pharmaceuticals
Deal Size : $621.0 million
Deal Type : Licensing Agreement